Peptide record

TPDB07020

Antibacterial Antifungal Hemolysis Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07020
Antibacterial Antifungal Hemolysis Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia Antifungipept CAFPdb PD_Hemolysis
standard
No
A 13-aa standard-residue multi-activity (Antibacterial, Antifungal, Hemolysis, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FLGALWNVWKSVF
Physicochemical Analysis

Sequence-only estimates for a linear peptide with free termini, not experimentally measured molecular properties. Mass and formula exclude cyclization and disulfide formation. The optical estimates assume paired cysteines, 280 nm, 1 g/L and a 1 cm path. The N-end rule estimate is not a measured plasma half-life.

C80H111N17O16
RDCEQHIMPTY
LFWV
1566.87
10.10
1
0
9
+1
-1.21
1.000
112.31
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
11000
7.02
2
Residue Composition
number
1
A
0
R
1
N
0
D
0
C
0
E
0
Q
1
G
0
H
0
I
2
L
1
K
0
M
2
F
0
P
1
S
0
T
2
W
0
Y
2
V
Amino Acid Distribution
A: 1 R: 0 N: 1 D: 0 C: 0 E: 0 Q: 0 G: 1 H: 0 I: 0 L: 2 K: 1 M: 0 F: 2 P: 0 S: 1 T: 0 W: 2 Y: 0 V: 2
Chemical Descriptors
13 reviewed residue count
C80H111N17O16 sequence-only estimate (linear, free termini)
1566.87 sequence-only estimate (linear, free termini)
10.10 sequence-only estimate (linear, free termini)
+1 sequence-only estimate (linear, free termini)
-1.21 sequence-only estimate (linear, free termini)
1.000 sequence-only estimate (linear, free termini)
Evidence Records 5 records
Evidence 1 Activity

Activity

MHC
Hemolysis
1.60 µM
[Ref.27912176]MHC=1.60µmol/L against human red blood cells

Target

human red blood cells

Source & Reference

Hemolytik PD_Hemolysis
DRAMP4
Eur J Med Chem. 2017 Jan 27 126:456-463.

Other

Source Activity Label Source Definition
Hemolysis
Hemolytik experimentally validated hemolytic peptide annotation.
Evidence 2 Activity

Activity

0% Hemolysis
Toxicity
1.6 µM
Hemolytic Cytotoxic
0% Hemolysis | 1.6 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel designed VmCT1 analogs with increased antimicrobial activity. | Eur J Med Chem | 2017
Evidence 3 Activity

Activity

90% Hemolysis
Toxicity
10 µM
Hemolytic Cytotoxic
90% Hemolysis | 10 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Novel designed VmCT1 analogs with increased antimicrobial activity. | Eur J Med Chem | 2017
Evidence 4 Activity

Activity

MHC
Toxicity
1.60 µm
Hemolytic
Hemolytic_activity: [Ref.27912176]MHC=1.60µmol/L against human red blood cells

Target

erythrocytes

Source & Reference

NA
DRAMP
Eur J Med Chem. 2017 Jan 27 126:456-463.
Evidence 5 Hemolysis

Activity

1.60 µM
MHC
[Ref.27912176]MHC=1.60µmol/L against human red blood cells
Hemolysis

Target

human red blood cells

Source & Reference

PD_Hemolysis
Eur J Med Chem. 2017 Jan 27 126:456-463.
DRAMP4
PD_Hemolysis